Drug intelligence / Profile preview

PVT301

Development stage: Preclinical
Lead developer: Parvus Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Peptides

Overview

PVT301 is an investigational peptide-major histocompatibility complex (pMHC) nanomedicine being developed by Parvus Therapeutics for the treatment of Celiac disease. Utilizing the proprietary Navacim platform, PVT301 consists of nanoparticles functionalized with disease-specific pMHC complexes. These complexes are designed to specifically engage T-cell receptors (TCRs) on pathogenic T cells, triggering their differentiation into disease-specific regulatory T cells (Tregs). This mechanism aims to restore immune tolerance to gluten-derived antigens and suppress the autoimmune response without causing systemic immunosuppression. PVT301 is currently in the preclinical/IND-enabling stage of development.

Targets

Autoantigen-specific T cell receptor recognizing PVT301 peptide–MHC class II complex

Beyond the preview

Go deeper on PVT301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT301.

Explore the full profile